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Abstract: Lobectomy and mediastinal lymph node dissection is the
standard surgical management of early stage non-small cell lung
cancer (NSCLC) because more limited resections have been asso-
ciated with a higher risk of local recurrence. Nevertheless, recent
lung cancer screening studies have led to the detection of an
increasing number of “very early” NSCLC (defined as less than 2
cm in size) and of good-prognosis histologic subtypes, bronchioloal-
veolar carcinoma (BAC), and adenocarcinoma (AC), mixed sub-
types that are potentially appropriate for sublobar resection. The
precise indications for sublobar resection remain unclear and are the
subject of ongoing clinical trials, but it seems that very early,
peripherally located, node-negative AC of a predominantly BAC
pattern may be adequately treated in this manner. Multifocal AC and
BAC, either synchronous or metachronous, are also effectively
treated by complete resection, using limited resections whenever
possible. The pneumonic form of BAC, the rarest variant of this
disease spectrum, continues to have a poor prognosis despite com-
plete resection. Very limited experience suggests that lung trans-
plantation leads to prolonged survival in highly selected patients
with this histologic subtype. To improve our management of very
early AC, much more information is needed about the molecular
abnormalities of AC and their relationship to clinical outcomes.
(J Thorac Oncol. 2006;1: S27–S31)
During the past decade, thoracic surgeons have beenconfronted with demographic and pathological shifts in
the group of non-small cell lung cancers (NSCLC) that are
potentially resectable.1 In many countries, adenocarcinoma
(AC) has become the most common NSCLC histology. The
proportion of women with lung cancer has increased dramat-
ically; in some institutions, half of all patients are female. The
number of patients who have never smoked or who have
minimal past tobacco exposure is also increasing, especially
in North America, because of tobacco control efforts. The
widespread use of computed tomography (CT) for lung can-
cer screening has also led to increased detection of “very
early” NSCLC, generally defined as tumors that are 2 cm or
less in size, which are usually ACs of mixed subtype or
bronchioloalveolar carcinomas (BAC) and which tend to
have an indolent clinical behavior.
These epidemiologic shifts have led thoracic surgeons
to reexamine the accepted tenets of surgical management of
early-stage NSCLC. As part of the November 2004 sympo-
sium on BAC, which is the subject of this supplement, a
group of thoracic surgeons were asked to review the current
management of BAC and very early ACs, focusing especially
on the role of sublobar resection. This paper summarizes the
discussions held at the symposium and provides updated
information on relevant clinical trials.
PATHOLOGICAL CLASSIFICATION OF AC:
RELEVANCE TO SURGICAL MANAGEMENT
BAC has long been recognized as a distinct form of AC
associated with a favorable prognosis. In 1989, the North
American Lung Cancer Study Group (LCSG) reviewed 1635
patients who had undergone resection of AC, 235 of whom
had BAC. Resectable BAC occurred more frequently in
never-smokers, was diagnosed at an earlier disease stage, and
was associated with a better survival rate than invasive AC.2
During the last 40 years, improved understanding of the
pathology of lung AC has prompted substantial changes in
the histologic subclassification by the World Health Organi-
zation (WHO), which are summarized by Travis et al.3 in
their report from the pathology panel of this symposium
(Table 1). From 1967 to 1999, multiple subcategories were
added to reflect increasing knowledge about the histologic
heterogeneity of AC. Significant changes in the 1999 WHO
classification included the addition of atypical adenomatous
hyperplasia (AAH) as a preinvasive lesion for lung AC, and
the requirement that all BACs demonstrate pure lepidic
growth without invasion of stroma, blood vessels, or pleura.
In 2004, AC mixed subtype was moved to the top of the list
of subcategories in recognition that this is now the most
common subtype.4
In 1995, Noguchi proposed a six-tier histologic sub-
classification (types A through F) for small ACs of the lung,
recognizing the excellent prognosis associated with BACs
(with a purely lepidic growth pattern), the adverse prognostic
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importance of central fibrosis in BACs, and the pathologic
heterogeneity of invasive ACs (Table 2).5 Although the 2004
WHO classification is the internationally accepted system,
Noguchi deserves credit for an early attempt to refine the
classification and to correlate it with clinical outcomes. As
discussed below, the Noguchi system is still used by Japanese
investigators to select patients for sublobar resection in on-
going clinical trials. More recently, Noguchi showed that
these histologic subtypes have corresponding molecular ab-
normalities.6 Areas of histologic types A, B, and C extracted
by microdissection from resected ACs were examined by
multiplex PCR-LOH and were found to have a progressive
rise in the incidence of allelic losses. Deletions of 3p, 17p,
18q, and 22q increased significantly from types A to C,
consistent with a model of malignant progression.
Several Japanese studies now confirm that the histo-
logic subtype correlates with CT findings and clinical out-
come.3,7–19 The results of Kodama exemplify these investi-
gations (Table 3). Taken as a whole, these studies suggest
that: 1) pure ground-glass opacities (GGO) on CT usually
represent BAC without any areas of invasive AC, whereas
lesions that show both GGO and solid components on CT
(part solid, part nonsolid) are mixtures of BAC and invasive
ACs; and 2) small (less than 2 cm in size) tumors with50%
GGO are associated with a 100% chance of being node
negative, have an excellent chance of long-term survival after
treatment, and probably can be managed by limited resection
rather than lobectomy. However, the appropriateness of lim-
ited resection for part solid/part nonsolid lesions is unclear
and is the subject of clinical trials in Japan. Tumors that are
more than 50% GGO on CT seem to have a better prognosis
and may potentially be managed by sublobar resection, but
preoperative high-resolution CT and intraoperative frozen-
section analysis still do not always accurately identify tumors
that have a poorer prognosis. Our uncertainties with respect
to the optimal surgical management of these lesions reflect
the highly variable presentation and behavior of lung ACs,
the limitations of CT findings in predicting pathologic find-
ings, and our lack of knowledge of the histologic and molec-
ular features that predict a poor prognosis.
TABLE 1. History of Lung Adenocarcinoma Subclassification
According to the World Health Organization
1967 Bronchogenic
Acinar
Papillary
Bronchioloalveolar
1981 Acinar adenocarcinoma
Papillary adenocarcinoma
Bronchioloalveolar carcinoma
Solid carcinoma with mucus formation
1999 Acinar
Papillary
Bronchioloalveolar carcinoma
Nonmucinous
Mucinous
Mixed mucinous and nonmucinous
Solid adenocarcinoma with mucin
Adenocarcinoma with mixed subtypes
Variants
Well-differentiated fetal adenocarcinoma
Mucinous (colloid) adenocarcinoma
Mucinous cystadenocarcinoma
Signet-ring adenocarcinoma
Clear-cell adenocarcinoma
2004 Adenocarcinoma, mixed subtype
Acinar adenocarcinoma
Papillary adenocarcinoma
Bronchioloalveolar carcinoma
Nonmucinous
Mucinous
Mixed nonmucinous and mucinous or indeterminate
Solid adenocarcinoma with mucin production
Fetal adenocarcinoma
Mucinous (colloid) adenocarcinoma
Mucinous cystadenocarcinoma
Signet-ring adenocarcinoma
Clear-cell adenocarcinoma
From Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology
and CT imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin
Oncol 2005;23:3279–3287. Used with permission.
TABLE 2. Noguchi’s Histology Typing of Small
Adenocarcinoma of the Lung
Type Description
A Localized bronchioloalveolar carcinoma
B Localized bronchioloalveolar carcinoma with foci of
collapse of alveolar structure
C Localized bronchioloalveolar carcinoma with foci of active
fibroblastic proliferation
D Poorly differentiated adenocarcinoma
E Tubular adenocarcinoma
F Papillary adenocarcinoma with compressive and destructive
growth
From Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the
lung. Histologic characteristics and prognosis. Cancer 1995;75:2844–2852. Used with
permission.
TABLE 3. Prognosis in Relationship to Appearance
(% GGO)
GGO < 50% GGO > 50% p
Patients 52 52 —
Size 13.7 12.3 0.09
Node involvement 8 0 0.01
% local resection 50% 70% 0.001
Relapse 9 0 —
DFS 72% 100% —
GGO, ground-glass opacity; DFS, disease-free survival.
Adapted from Kodama K, Higashiyama M, Yokouchi H, . Prognostic value of
ground-glass opacity found in small lung adenocarcinoma on high-resolution CT
scanning. Lung Cancer 2001;33:17–25. Used with permission.
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RELATIONSHIP OF TUMOR SIZE TO TUMOR
STAGE: SURGICAL IMPLICATIONS
In NSCLC, the size of the primary tumor is known to
correlate with the likelihood of lymph node metastases and,
therefore, to influence consideration of sublobar resection.
The frequency of nodal disease in very early NSCLC has
been studied extensively.20–32 Although lymph node involve-
ment is relatively uncommon in small AC, approximately
10% of tumors that are 1 cm or smaller and 20% of tumors
that are 1 to 2 cm in size have nodal metastases (Tables 4 and
5). Relative to AC, squamous cell carcinomas less than 2 cm
in size seem to be associated with a lower risk of nodal
disease.20 These findings complicate the selection of patients
for limited pulmonary resection because we do not fully
understand which patients with very early lung AC may have
disease in the intralobar lymphatics or regional nodes. A
better understanding of the molecular features in early AC
and their relationship to clinical outcome is needed to allow
accurate decisions about the use of sublobar resection.
LOBECTOMY VERSUS SUBLOBAR RESECTION:
CURRENT KNOWLEDGE AND INVESTIGATIONS
A prospective randomized multicenter trial reported by
the LCSG in 1995 established lobectomy as the standard
approach to resection for T1N0 NSCLC (LCSG trial 821).
Sublobar resection, either wedge resection or segmentec-
tomy, for carefully selected patients who had thorough intra-
operative evaluation of the extent of the primary tumor and of
the N1 and N2 lymph nodes, was associated with a tripling of
the local recurrence rate and a 30% increase in the overall
death rate. Within the T1 stage category, tumor size did not
seem to influence the risk of recurrence, but the numbers of
patients who had tumors less than 2 cm in size were small.33
The increasing incidence of very early NSCLC seen in
thoracic surgical practice, primarily via CT screening for lung
cancer,1 has reopened the debate about the use of sublobar
resection. This debate is especially relevant to BAC and to
some AC of mixed subtype because of their indolent clinical
behavior and known propensity for multifocality. Patients
with these AC histologic subtypes often have synchronous or
metachronous primary tumors that are best managed by
resection. Preservation of lung function through the proper
use of limited resection can be a critical aspect of achieving
prolonged survival and maintaining patients’ functional ca-
pacity.34–36 Several retrospective studies and prospective
clinical trials suggest that the sublobar resection may be an
appropriate operation for very early AC.11,13,37–40 The param-
eters that currently seem to allow proper selection of patients
for limited resection include tumor size (less than 2 cm and
especially 1 cm or less) in combination with tumor histology
(BAC or AC, mixed subtype with 50% or greater BAC
component or AC, Noguchi types A or B), peripheral tumor
location, and absence of N1 or N2 disease based on thorough
intraoperative staging. The presence of GGO or of part solid,
part nonsolid appearance on CT reflects these tumor charac-
teristics. In ways that are not yet fully understood (aside from
the presence of EGFR mutations in some tumors), these
clinical and pathologic features represent tumors that most
likely have an indolent biological behavior. The adequacy of
wedge resection versus anatomical resection via segmentec-
tomy remains undefined, although segmentectomy has been
favored in Japanese studies because it provides an optimal
deep margin of resection and removes the local lymphatic bed
associated with the primary tumor.39
Japanese investigators have sought to confirm these
selection criteria for sublobar resection through prospective
multicenter clinical trials. JCOG trial 0201 (Figure 1), re-
ported at the 2006 meeting of the American Society of
Clinical Oncology (ASCO), enrolled patients with clinical
TABLE 4. Prevalence of Nodal Disease in Solid Nodules
2 cm in Size
n % Positive Nodes % N2
Naruke (1993)23 287 40 50
Asamura (1996)24 174 20 60
Konaka (1998)25 171 17.5 66
Takizawa (1998)26 157 17 NS
Sugi (1998)27 115 19 66
Wu (2001)28 136 22 NS
Okada (2003)29 265 18 55
Nonaka (2003)30 46 28 70
Average 23
NS, not stated.
TABLE 5. Prevalence of Nodal Disease in Solid Nodules
1 cm or Less in Size
n
Patients with Positive
Nodes (%)
Naruke (1993)23 20 8 (16)
Oda (1998)31 22 0 (0)
Konaka (1998)25 19 0 (0)
Ohta (2001)20 11 4 (4)
Miller (2002)32 100 7 (7)
Average 9
FIGURE 1. Schema for JCOG 0201 trial.
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stage IA AC.41 The primary endpoint was to determine the
specificity of high-resolution CT (HRCT) in diagnosing non-
invasive AC, using the final pathologic findings as the refer-
ence standard. A pathological noninvasive AC was defined as
a tumor with no lymph node metastases or lymphatic or
vascular invasion. Preoperative evaluation included HRCT to
assess the presence of GGO and to calculate the ratio of GGO
to solid component of the tumor. Patients then underwent
lobectomy and mediastinal lymph node dissection. Final
pathological findings were compared with the HRCT features
to determine whether the CT could be used to select patients
appropriately for sublobar resection. Of the 811 patients
enrolled, 545 eligible patients had undergone lobectomy and
central data review at the time of the ASCO presentation.
Comparison of the CT with the pathological findings showed
that HRCT had a specificity of 98.3% but a sensitivity of only
24.7% for the diagnosis of noninvasive AC.
The results of JCOG 0201 have been utilized to develop
two new prospective trials. Patients found to have AC 2cm or
less in size that are predominantly GGO by HRCT (solid
component less than 25% of entire tumor) will be entered on
a single arm Phase II trial testing the use of wedge resection
for these highly curable indolent tumors. Patients found to
have AC 2cm or less in size that have a larger solid compo-
nent on HRCT (more than 25% but less than 100% of the
entire tumor) will be eligible for a prospective randomized
comparing lobectomy to limited resection (Figure 2). These
trials might also help define which tumors do not require
lymph node dissection or sampling, although this is not a
planned study endpoint. At the current time lymph node
sampling or systematic nodal dissection (SND) remains a key
part of accurate tumor staging.42
In North America, the Cancer and Leukemia Group B
(CALGB), in collaboration with the American College of
Surgeons Oncology Group (ACOSOG), is planning a pro-
spective randomized trial comparing lobectomy versus lim-
ited resection (wedge or segmentectomy) for patients with
AC 2 cm or less in size. This trial does not incorporate the
nuanced radiological and histologic selection criteria used in
Japanese studies, depending instead on simple size criteria
and the basic diagnosis of AC. Designed to reproduce the
LCSG 821 trial, but with a focus on smaller tumors, the
CALGB trial uses intraoperative assessment of tumor size,
tumor location, and nodal involvement, followed by random-
ization to lobectomy or limited resection. Because of the
large numbers of patients and long follow-up time required to
identify a survival difference between these two resectional
approaches, results from this trial will probably not be avail-
able for about 8 years.
MANAGEMENT OF THE PNEUMONIC FORM
OF BAC: RESECTION, SYSTEMIC THERAPY, OR
TRANSPLANTATION?
Most BAC or AC, mixed subtype present as either a
single nodule or as multiple lung nodules (synchronous or
metachronous) that behave in an indolent manner and are best
managed surgically.34,36,43 The least common variant of this
BAC-AC disease spectrum is generally termed the pneumo-
nic form because it presents as a progressive lobar consoli-
dation with mucinous AC filling the alveolar spaces. Resec-
tion does not seem to alter the very poor prognosis of this
disease, which inevitably progresses to consolidation of both
lungs and death from respiratory failure.34,43 Systemic ther-
apy has also been relatively ineffective in this disease. Thus,
most surgeons are reluctant to consider pulmonary resection for
this biologically aggressive form of AC. Lung transplantation
has been suggested as a potential treatment option. First reported
by Zorn et al., lung transplantation in nine patients (single lung
in two and bilateral transplants in seven patients) was associated
with a poor outcome.44,45 Only two patients survived long term,
whereas the other patients experienced cancer recurrence in the
transplanted lungs. More recently, the Toronto group reported
their experience with transplantation in 29 patients.46 Five-year
survival was 51%, and recurrence developed in 13 of the
transplanted lungs. Although transplantation was performed
for advanced multifocal BAC, it is not entirely clear how
many of these patients truly had the pneumonic form of
mucinous AC. Thus, lung transplantation potentially remains
an option for selected patients, but it is associated with a
significant risk of recurrent disease and requires further study.
SUMMARY
Lobectomy and lymph node sampling or systematic
nodal dissection remain the standard surgical treatment for
patients with early stage NSCLC. However, limited resection
may be an appropriate option for patients with very early AC
and BAC based on tumor size, location, and relative propor-
tion of BAC to AC. Very small BAC are probably appropri-
ately treated by limited resection. Accurate criteria for select-
ing patients for limited pulmonary resection await the results
of ongoing clinical trials and an improved understanding of
NSCLC biology in relationship to clinical outcome.
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